– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. –– Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment –– Multiple authorized treatment centers activated –BOSTON & ZUG, Switzerland (BUSINESS WIRE) Vertex Ph.
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.